🔗 Share this article

As America undertakes unprecedented revisions to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccinations in the pandemic and has zeroed in on possible fatalities after Covid immunization in her brief tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Schedule

Health officials planned to reveal sweeping changes to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, sources say – a major change that would put the US at odds with many the world with no evidence for public health gain. This reveal has been delayed until the next year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to address the audience at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the FDA – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has repeatedly called for discontinuing certain childhood vaccine recommendations in the US to become more in line with Denmark's approach, a country with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Background

The appointee has no obvious background in pharmaceutical research, oversight or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She has no expertise in managing a large organization. She lacks background in drug approvals.”

Past directors of the center would “be deeply familiar with laws and regulations and the research of drug development”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who ran the center have had.”

This division has an immense range of responsibilities at the FDA, Woodcock stated.

“Many people just pays attention on the innovative therapies, but the off-patent medication office clears a multitude of generic medications. There’s a biosimilars program, OTC medication office and so forth, and all of those must be supervised,” she explained. “The area you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a major leadership aspect to the job, which supervises over 5,000 employees. “It’s a massive administrative position, if you execute it properly,” Woodcock said.

Official Statement and Disputed Programs

Regarding inquiries about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among agency officials on vaccines, a spokesperson responded that the “concerns stem from incorrect presumptions”.

“Her experience aligns with the responsibilities of her job,” the representative explained, noting the months Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a contentious one-day therapy clearance system that allegedly troubled her preceding directors. “How are these medications being chosen for this fast-track system? Who makes the calls?” Howard questioned. “There’s a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he said, “the FDA looks to be trending towards laxer rules of pharmaceuticals, with the exception of vaccines.”

Documented Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, track record, Howard observe. She released a analysis using non-validated public submissions to assess the frequency of heart inflammation following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the current administration encompassed altering guidelines for recently developed shots and discontinuing “optional” immunizations, she remarked following the vote on a audio program. At the agency, Høeg has reportedly suggested preventing adolescent males from receiving Covid vaccinations.

“She is an thorough dogmatist who starts off with her beliefs and tailors the evidence to accommodate the evidence in a highly deceptive, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|